Breckenridge Pharmaceutical, Inc. Announces Entry Into Injectable Market With The Immediate Launch Of Methylergonovine Maleate Injection

Published: Nov 10, 2016

BOCA RATON, Fla., Nov. 9, 2016 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Methylergonovine Maleate Injection, USP 0.2mg/mL. This product is an AP rated generic to Methergin®, a product owned by Edison Therapeutics, LLC. and is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage. Breckenridge is launching this product in conjunction with the ANDA holder, Ergoject, LLC.

This launch is the first of several planned injectable products the company plans to launch in the near future and showcases the investment the company made in hiring David Giering, Director, Institutional Sales and Trade Relations, over a year ago.  David brings more than 15 years of experience in the pharmaceutical industry, including branded institutional sales, wholesaler category management, and most recently with a major generic pharmaceutical company, managing its injectable portfolio. 

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held own label Distributor that performs pharmaceutical research and development as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays and powders.

*All brand names and trademarks are the property of their respective owners.

To view the original version on PR Newswire, visit:

SOURCE Breckenridge Pharmaceutical, Inc.

Back to news